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 27 
Abstract 28 
Staphylococcus pseudintermedius causes opportunistic infections in dogs. It also has 29 
significant zoonotic potential, with the emergence of multidrug-resistance leading to 30 
difficulty treating both animal and human infections. Manuka honey has previously been 31 
reported to inhibit many bacterial pathogens including methicillin resistant Staphylococcus 32 
aureus and is successfully utilised in both clinical and veterinary practice.  Here we evaluated 33 
the ability of manuka honey to inhibit strains of S. pseudintermedius growth alone and in 34 
combination with antibiotics, and its capacity to modulate virulence within multiple S. 35 
pseudintermedius. All 18 of the genetically diverse S. pseudintermedius strains sequenced 36 
and tested were inhibited by ≤ 12% (w/v) medical grade manuka honey, although tolerance to 37 
five clinically relevant antibiotics was observed. The susceptibility of the isolates to four of 38 
these antibiotics was significantly increased (p ≤0.05) when combined with sub lethal 39 
concentrations of honey, although sensitivity to oxacillin was decreased. Virulence (DNase, 40 
protease and haemolysin) activity was also significantly reduced (p ≤ 0.05) in over half of 41 
isolates when cultured with sub lethal concentrations of honey (13, 9 and 10 isolates 42 
respectively).  These findings highlight the potential for manuka honey to be utilised against 43 
S. pseudintermedius infections. 44 
 45 
Importance 46 
Staphylococcus pseudintermedius is an important member of the skin microbial community 47 
in animals and can cause opportunistic infections in both pets and their owners. The high 48 
incidence of antimicrobial resistance in S. pseudintermedius highlights that this opportunistic 49 
zoonotic pathogen can cause infections which require prolonged and intensive treatment to 50 
resolve. Manuka honey has proven efficacy against many bacterial pathogens and is an 51 
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accepted topical treatment for infections in both veterinary and clinical practice so is a 52 
particularly appropriate antimicrobial for use with zoonotic pathogens such as S. 53 
pseudintermedius. Here we demonstrate that manuka honey is not only highly potent against 54 
novel multi-drug resistant S. pseudintermedius isolates, but also acts synergistically with 55 
clinically relevant antibiotics. In addition, manuka honey modulates S. pseudintermedius 56 
virulence activity, even at subinhibitory concentrations. In a clinical setting these attributes 57 
may assist in controlling infection, allowing a more rapid resolution and reducing antibiotic 58 
use.  59 
 60 
Keywords: manuka honey, antibiotic resistance, synergy, haemolysis, proteolysis, 61 
aggregation 62 
 63 
Introduction 64 
Staphylococcus pseudintermedius is a commensal bacterium of the skin and mucous 65 
membranes of up to 80% of dog populations [1] and is frequently associated with 66 
opportunistic veterinary infections such as post-surgical infections and pyoderma [2, 3]. 67 
Increasingly, methicillin resistant S. pseudintermedius (MRSP) is being isolated from these 68 
infections, and reports now indicate that S. pseudintermedius isolates display resistance to a 69 
range of antibiotics including: erythromycin, clindamycin, ciprofloxacin and gentamicin [4]. 70 
This resistance to multiple classes of antibiotics has made S. pseudintermedius a global 71 
clinical challenge in veterinary medicine as treatment of infections is increasingly 72 
problematic. The prevalence of S. pseudintermedius has implications that reach beyond the 73 
veterinary field as studies have shown that S. pseudintermedius can cause zoonotic infections 74 
in humans, making it a significant one health issue [5, 6].  75 
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The zoonotic potential of this organism has only recently been recognised as S. 76 
pseudintermedius infections in humans have previously been misidentified as Staphylococcus 77 
aureus due to their phenotypic similarities and coagulase positivity [7]. They share traits such 78 
as acquired methicillin resistance, ability to form biofilms, modulation of the host immune 79 
system and production of proteolytic enzymes and toxins [8]. Recent advances in diagnostics 80 
have allowed clearer separation of the two species and have shown that, as well as a zoonotic 81 
agent, S. pseudintermedius is able to colonise the nasal passageways of humans. This 82 
colonisation provides a reservoir for reinfection of both animals and humans, and a potential 83 
reservoir for antimicrobial resistance gene transfer [9]. As S. pseudintermedius exhibits a 84 
decreasing level of antibiotic susceptibility and can cause severe infection in both animals 85 
and humans there are grounds for evaluating whether new strategies or novel antimicrobial 86 
agents could be used to enhance treatment options [10].  87 
Manuka honey is used as a topical antimicrobial agent for infections in both humans and 88 
animals, exhibiting activity against a wide range of pathogens [11]. Antimicrobial activity is 89 
due to the presence of multiple antimicrobial compounds within the honey, the best studied of 90 
which is methylglyoxal, alongside its high osmotic potential (for a review of the activity of 91 
manuka honey see [12]). Manuka honey has been used to successfully eradicate S. aureus 92 
infections in the clinic and can inhibit the growth of methicillin resistant S. aureus (MRSA) 93 
and Pseudomonas aeruginosa at a low concentrations in vitro [13, 14]. The mode of action of 94 
manuka honey against MRSA has been partially elucidated; and due to the phenotypic 95 
similarity between S. aureus and S. pseudintermedius is highly likely to be similarly effective 96 
in inhibiting S. pseudintermedius and MRSP [15]. More recently studies have also 97 
highlighted the ability of manuka honey to increase efficacy of some clinically relevant 98 
antibiotics against MRSA which could also be useful in the case of difficult to treat antibiotic 99 
resistant S. pseudintermedius infections [15]. In parallel, manuka honey has been utilised by 100 
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the veterinary community, in particular for treatment of equine wounds [16]. Previous work 101 
has demonstrated in vitro activity against a wide range of equine bacterial isolates [17] with 102 
in vivo activity also recently reported [18]. 103 
Here we aimed to establish whether manuka honey could inhibit the growth of a range of 104 
genetically diverse S. pseudintermedius, increase the sensitivity of clinical S. 105 
pseudintermedius isolates to a range of antibiotics and reduce expression of key virulence 106 
factors. Activity in these areas would indicate potential for manuka honey in the treatment of 107 
difficult to treat infections caused by S. pseudintermedius.  108 
 109 
Results 110 
Genome sequencing highlighted that isolates were genetically diverse and contained 111 
novel MLST sequences 112 
As these isolates have not previously been reported they were sequenced in order to 113 
interrogate their multilocus sequence typing (MLST) and antimicrobial resistance (AMR) 114 
profiles and detect how closely related the isolates were genetically. Sequencing reads and 115 
genome assemblies from this study are available from NCBI via the BioProject record 116 
PRJNA561036. MLST allele sequences were derived from assemblies and submitted to the 117 
Staphylococcus pseudintermedius PubMLST database. New allele sequences were detected 118 
for the pta loci of isolate C and the ack loci of isolate G. A total of 10 novel sequence types 119 
(ST) were identified within this dataset with a further 8 STs identified, 4 of which belonged 120 
to ST71 (Assembly and MLST information found in Supplementary Table 1). A summary 121 
table showing the different antibiotic resistance genes present in each isolate can be seen in 122 
table 1.  123 
 124 
 125 
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(Table 1) 126 
 127 
A core genome SNP phylogeny accounting for the removal of detected recombination and 128 
consisting of the isolates documented within this study along with Staphylococcus 129 
pseudintermedius genome assemblies displayed very little obvious clustering of isolates 130 
based on geographical location or the health status of the individual from which they were 131 
isolated (Figure 1).  132 
 133 
(Figure 1) 134 
 135 
Minimum inhibitory/bactericidal concentration testing of honey and antibiotics showed 136 
universal activity of honey against the S. pseudintermedius isolates tested. 137 
Previous work by our group indicates that manuka honey has antibacterial activity against 138 
Staphylococcus sp., including, antibiotic resistant (AMR) isolates [11, 13]. In this study all 18 139 
isolates of S. pseudintermedius demonstrated susceptibility to low concentrations of manuka 140 
honey ≤ 12 % (w/v), with 9/18 inhibited at 12% w/v and 9/18 inhibited at 10% w/v manuka 141 
honey. No antimicrobial activity was detected at concentrations of less than 8 % w/v manuka 142 
honey. The minimum bactericidal concentration was ≤ 12% (w/v) manuka honey for all 143 
isolates.  144 
The sensitivity of the S. pseudintermedius isolates to tetracycline, penicillin, 145 
chloramphenicol, gentamicin and oxacillin was also determined. For tetracycline, penicillin 146 
and gentamicin more  than half of the isolates tested (9, 16 and 11  isolates respectively) had 147 
breakpoints that indicated resistance according to the European Committee on Antimicrobial 148 
Susceptibility Testing (EUCAST) guidelines. Only chloramphenicol and oxacillin remained 149 
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effective against a majority of isolates with 10 and 14 isolates remaining susceptible 150 
respectively.  151 
Assessment of antibiotic interactions showed that honey was able to increase the activity 152 
of the majority of antibiotics tested 153 
There has been significant recent interest in combination therapy, combinations of antibiotics 154 
with other antibiotics, peptides and plant extracts, to increase antibiotic efficacy [19, 20]. 155 
Since the isolates within the collection tested here display a high level of resistance to 156 
commonly used antibiotic treatments, it was speculated that antibiotic efficacy might be 157 
improved if used in combination with sub lethal concentrations of manuka honey.  158 
Manuka honey increased the sensitivity of a number of isolates to various antibiotics, with 159 
small but statistically significant increases in zone size observed for the majority of isolates 160 
(Figure 2 and Supplementary figure 1). The exact increase in suceptability was both strain 161 
and antibiotic specific, full details of the inhibition of each isolate to the five antibiotics with 162 
and without honey is shown in Supplementary figure 1. The numbers of isolates which 163 
displayed significantly larger zones of inhibition (p  ≤ 0.05) when treated with sub lethal 164 
concentration of honey (5% w/v) combined with antibiotic compared to antibiotic alone were: 165 
tetracycline 89% (16/18), penicillin 56% (10/18) chloramphenicol 83% (15/18) gentamicin 166 
67% (12/18). In some instances (isolates C, D, E, K, M and X  for tetracycline and isolates O 167 
and X for Chloramphenicol) the isolates showed complete resistance to the antibiotic in 168 
standard medium, however in the presence of subinhibitory honey a zone of inhibition was 169 
present. When manuka honey was used in combination with oxacillin none of the isolates 170 
displayed increased sensitivity and 33% (6/18) isolates showed significantly decreased 171 
sensitivity (Figure 2) data for individual isolates in supplementary figure 1.  172 
 173 
(Figure 2) 174 
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 175 
 176 
Generally, there was a good correlation between the AMR phenotype observed in the disc 177 
diffusion assays and the genotype of each isolate. There were several instances where 178 
discrepancies between genotype and phenotype were detected but only two are of note. 179 
Firstly, no beta lactam inhibiting genes were detected in isolate G despite a clear phenotypic 180 
resistance to penicillin but not oxacillin. There was a similar observation for isolate X, which 181 
was phenotypically resistant to chloramphenicol, despite no identifiable resistance gene being 182 
identified encoding chloramphenicol inactivation enzymes (acquired genes) (Supplementary 183 
table 1). Thus, in this case, 50S ribosomal subunit mutational effects are the likely resistance 184 
source.  185 
Characterisation of virulence factor activity indicated that manuka honey was able to 186 
reduce activity of several key virulence factors 187 
Alongside its antimicrobial activity, manuka honey has previously been shown to affect 188 
protein and gene expression in the closely related S. aureus [21]. It was therefore of interest 189 
to determine if manuka honey could elicit phenotypic changes in the virulence profile of S. 190 
pseudintermedius isolates. Initially the haemolytic, protease, lipase and DNase activity of the 191 
isolates was assessed without manuka honey, alongside the isolate’s ability to aggregate (a 192 
property linked to biofilm formation).  193 
All 18 isolates showed haemolytic, proteolytic, DNase, and aggregation activity. None of the 194 
isolates demonstrated lipase or lecithinase capabilities (data not shown). The activity was 195 
then reassessed using a sub lethal concentration (5% w/v) of manuka honey. As with the 196 
antibiotic activity (Figure 2), the presence of subinhibitory concentrations of honey were able 197 
to elicit alterations in the virulence activity of the S. pseudintermedius isolates. As with the 198 
alterations in antibiotic susceptibility, alterations in virulence activity appeared to be highly 199 
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isolate specific. In most of the isolates the observed effects were subtle, although statistically 200 
significant. However, four of the strains showed a complete reduction of haemolysis (strains 201 
G and H) or proteolysis (Strains B and C) activity. Two further strains (D and F) showed 202 
complete reduction of both haemolysis and proteolysis. The number of isolates which had 203 
significantly changed haemolysis, proteolysis and DNase activity p = ≤ 0.05 respectively 204 
when grown in sub lethal concentration of honey (5% w/v) compared to control cells were: 205 
haemolytic 56% (10/18), protease 50% (9/18) and DNase 72% (13/18) (Figure 3 and 206 
Supplementary figure 2).  207 
 208 
(Figure 3) 209 
 210 
Sub inhibitory concentrations of manuka honey inhibited aggregation and reduced 211 
mature biofilm biomass of S. pseudintermedius suspensions 212 
All 18 isolates displayed the ability to agglutinate. After 24 hours incubation control isolates 213 
had a mean optical density of 25 % of the 0 hours value, indicating that bacterial cells had 214 
agglutinated, leading to a decreased OD600 (Figure 4A). In contrast, 15 of the isolates 215 
displayed a significantly reduced ability to agglutinate (p = ≤0.001) after incubation with a 216 
sub lethal (5 % w/v) concentration honey, with a mean optical density of 65 % of the 0-hour 217 
value (Figure 4A).  Total viable cells counts after 24 hours of  incubation with and without 218 
manuka honey highlighted that the increased optical density was not linked to an increase in 219 
cell numbers, with total viable counts indicating that ~ 4 x 107 CFU/ml viable cells remained 220 
in each vessel following incubation. With the exception of isolates B and H which were 221 
moderate biofilms formers and isolate O which was a weak biofilm former, all the isolates 222 
were strong biofilm formers as defined by Stepanovic et al [22].  223 
 224 
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 225 
(Figure 4) 226 
 227 
As expected, the concentrations of manuka honey needed disrupt established (24 h) biofilm 228 
was higher than the MIC (Figure 4B). There was a reduction in biomass at concentrations of 229 
≥ 20% w/v manuka honey, with reductions becoming significant (p = ≤ 0.01). at 230 
concentrations of ≥ 30/%. 231 
 232 
Discussion 233 
The increase in S. pseudintermedius antibiotic resistance is of concern to both clinicians and 234 
veterinarians [23, 24]. New strategies for infection control are required and a one health 235 
approach must be utilised during discovery to ensure that therapeutics can be used 236 
harmoniously across medical disciplines. Clinicians and veterinarians have previously been 237 
criticised for excessive use of antibiotics [25], and following the publication of the review on 238 
antimicrobial resistance [26] there has been a drive to improve collaboration between 239 
medical, veterinary and agricultural disciplines [27] in addressing the issue of AMR. The 240 
report by O'Neill [26] also highlighted that the development of novel therapeutics to enhance 241 
the activity of, or replace antibiotic treatments, was an essential strategy to preserve our 242 
ability to effectively treat infectious diseases. 243 
Zoonotic pathogens are of concern, since inappropriate treatment and resolution of animal 244 
infections has the potential to increase disease severity and recalcitrance to treatment of any 245 
subsequent human infection. Other members of the staphylococcus genus, such as S. aureus 246 
and S. epidermidis, are persistent colonisers of the human body, causing significant morbidity 247 
and mortality, and display high levels of AMR. S. pseudintermedius has also been shown to 248 
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colonise healthy humans [28] and appears to have similar disease progression and resistance 249 
patterns to other members of the genus [23, 24, 29]. 250 
The S. pseudintermedius in this study showed a wide range of genetic diversity (Figure 1), 251 
including the presence of several novel MLST combinations. The genetic diversity of these 252 
samples allowed an estimation of how effective manuka honey might be for treatment of S. 253 
pseudintermedius infections as multiple strains of S. pseudintermedius with varied antibiotic 254 
resistance profiles can co-colonise at an infection site [30].  The majority of isolates also 255 
contained genes known to confer antibiotic resistance, with many isolates also showing 256 
phenotypic resistance to one or more of the antibiotics tested. Only in a couple of instances 257 
was there a discrepancy between the phenotypic resistance patterns and the presence of 258 
acquired AMR genes. However, since the genomes presented within this paper are not closed 259 
it is possible that genes are present in regions of the genome currently unassembled. Further, 260 
presence of point mutations giving rise to resistance were not screened for and thus could 261 
offer alternative resistance strategies.  262 
The results presented here provide evidence that low concentrations of manuka honey can 263 
inhibit the growth of clinical isolates of S. pseudintermedius, with a bactericidal mode of 264 
action. All isolates displayed sensitivity to manuka honey and had a range of sensitivities to 265 
the conventional antibiotics tested. This is in line with previous studies which have 266 
demonstrated that manuka honey can inhibit S. aureus, MRSA and vancomycin-intermediate 267 
S. aureus (VISA) at low concentrations [31-33]. The only study looking at the ability of 268 
manuka honey to inhibit S. pseudintermedius was by Uri et al [34] which showed a low level 269 
of antibacterial activity. However, this was likely to be due to issues with the homogeneity of 270 
the honey solution used in the study as highlighted by the authors of that paper and not a true 271 
reflection of poor manuka honey efficacy, particularly given the many in vitro and in vivo 272 
studies showing efficacy against other bacterial species [11, 13, 21].   273 
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The results of the antibiotic susceptibility testing presented here reflect the general trend of 274 
increased antimicrobial resistance seen globally, with 88% of the isolates tested displaying 275 
resistance to two or more of the antibiotics (Figure 2). The levels of resistance for gentamicin 276 
and chloramphenicol presented here are broadly similar to findings from earlier studies where 277 
S. pseudintermedius resistance to chloramphenicol and gentamicin was ~75 and 55% 278 
respectively, whereas the levels of resistance for tetracycline were lower in this study at ~50 279 
% than those previously reported (94.2%) [35, 36] . There were only four MRSP isolates 280 
within our collection, a lower incidence of resistance than previously reported [35, 36].  281 
In addition to obtaining the sensitivity profiles of these bacteria and in view of the growing 282 
interest in the use of topical and combination therapies for staphylococcal infections [37] the 283 
ability of manuka honey to enhance antibiotic activity was tested. Our results highlight that 284 
sub lethal concentrations of honey are capable of significantly improving (p < 0.05) the 285 
activity of antibiotics from a variety of classes, for most isolates tested (Figure 2).  The 286 
exception to this was oxacillin, in which combination with honey showed no improvement in 287 
activity against any of the MRSP isolates.  Importantly, in six of the methicillin susceptible S. 288 
pseudintermedius (MSSP) isolates manuka honey was associated with a significant decrease 289 
in the efficacy of oxacillin, although the isolates did remain sensitive to oxacillin according to 290 
the breakpoints.  This was an unexpected finding as previous studies have identified synergy 291 
between honey and oxacillin when tested against MRSA, as well as reporting a possible 292 
mechanism of action for this synergy through the MecR1 pathway [32, 38]. It is interesting to 293 
note that synergy has been observed for MRSA with mecA mechanism of resistance 294 
previously, and the four MRSPs here all have resistance mediated by mecA (supplementary 295 
table 1) the same as seen in the MRSA, so a similar response would have been expected, this 296 
difference in response could be investigated further in future work. The fact that the isolates 297 
with the altered response are phenotypically methicillin sensitive, and therefore unlikely to 298 
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contain a functioning mecR1 gene, highlights why the response is different to that previously 299 
observed. The mecR1 gene has not shown to be common within S. pseudintermedius isolates, 300 
with a recent study only detecting it in 7 of 17 isolates tested [39]. It has also been observed 301 
that some MRSP do also not contain mecR1 [40], again showing that even where isolates do 302 
have phenotypic resistance to penicillin’s, honey may not be able to act on them via the 303 
previously described MecR1 pathway. This reduction in sensitivity to oxacillin when exposed 304 
to sub lethal concentrations of manuka honey is an important observation for medical 305 
practice, where oxacillin is a commonly used treatment, as it suggests that using manuka 306 
honey in combination with the other antibiotics tested here would be more effective then 307 
oxacillin as a potential combination therapy. Our observation also highlights the need, 308 
previously stressed within the O’Neill Report [26], for novel bedside diagnostic tools in order 309 
to better determine suitable treatments for patients presenting with infection. If clinicians are 310 
able to rapidly distinguishing between opportunistic infections caused by S, aureus and S. 311 
pseudintermedius then suitable combination therapies can be selected, improving clinical 312 
outcome and reducing the opportunity for microbial persistence. Within veterinary practise, 313 
where S. pseudintermedius infection is more commonly encountered, oxacillin is not 314 
considered for first line treatment of skin infections [41] and so our observation is of less 315 
significance. It should also be noted that our data did not show decreased susceptibility to 316 
penicillin, indicating that manuka honey/oxacillin combination therapies may not be suitable 317 
for treatment of S. pseudintermedius, this is unlikely to be the case for all penicillin’s. 318 
Investigation into the mechanism by which honey is inhibiting S. pseudintermedius might 319 
shed light onto why there is this discrepancy between S. pseudintermedius and S. aureus 320 
when treated with oxacillin and honey; potentially genetic variation in the two species might 321 
account for the reduced efficacy of the combination in this case.  Despite this and given the 322 
high levels of antibiotic resistance increasingly being reported, the results presented here 323 
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show that there is real potential for honey to be used alone or as a topical adjuvant to certain 324 
antibiotic treatments to help improve antibiotic efficacy against S. pseudintermedius 325 
infections.   326 
Alongside investigation of synergy, antivirulence compounds are of great interest as they 327 
reduce pathogenicity while leaving bacterial growth unaffected and desirable host microbes 328 
unharmed [42]. As S. pseudintermedius are known to produce a range of virulence factors 329 
which enhance their ability to cause severe disease in both animal and humans [23, 43] the 330 
effect of sub lethal concentrations of manuka honey on the activity of virulence factors in S. 331 
pseudintermedius was tested. Investigating the effect of sub lethal concentrations of honey on 332 
virulence provided novel evidence that honey can significantly reduce virulence factor 333 
activity in some S. pseudintermedius isolates (Figure 3). In infection the ability to produce an 334 
extensive array of virulence factors allows bacteria to break down host tissue, evade the 335 
immune system and acquire host nutrients [5, 44]. The isolates in this study all displayed 336 
varying levels of β haemolytic, protease, DNase activity as well as the ability to auto 337 
agglutinate.  They were all negative for lipase and lecithinase activity, correlating well with 338 
previous findings charting the virulence profiles of S. pseudintermedius isolated from humans 339 
and dogs [45]. The data presented here establishes that sub lethal concentrations of honey 340 
significantly reduced haemolysin activity in half the S. pseudintermedius isolates tested, 341 
indicating a strain specific mode of action. As there was a significant increase in haemolytic 342 
activity of one isolate further work would be needed before this could be considered of 343 
interest in a clinical setting. To date there is little evidence of the role of β-haemolysin in S. 344 
pseudintermedius pathogenicity. In S. aureus β haemolysin production promotes efficient 345 
skin colonisation [46]. It is also thought to cause host cell cytotoxicity, act as a biofilm ligase 346 
and conferring a selective advantage to those strains which produce it [47].  It is logical to 347 
suggest that ability of honey to reduce β haemolytic activity would thereby reduce the 348 
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capability of S. pseudintermedius to colonise host cells and cause cytotoxicity and reduce 349 
zoonotic transmission. 350 
Similarly, the results presented here show that sub lethal manuka honey significantly reduces 351 
the ability of half the S. pseudintermedius strains to produce protease and did not increase 352 
protease activity in any of the other strains.  As the ability of staphylococci to produce 353 
proteases has been linked to their ability to evade host immunity as well as cleaving host 354 
proteins and contributing to bacterial dissemination within the host [48, 49] reduction in this 355 
activity could be clinically relevant. Previously published work showed that protease null 356 
mutants of S. aureus have decreased virulence and reduced dissemination and invasion in 357 
vivo [50]. S. pseudintermedius produces a similar range of proteases and, if they perform an 358 
analogous role to those seen in S. aureus, then honey could have an important function in 359 
decreasing the severity of localised infection and reducing the spread of S. pseudintermedius 360 
within the host.  361 
Linked to infection duration and antibiotic tolerance is DNase activity, which has been 362 
reported to aid in the formation of bacteria aggregates, maintenance of biofilm [51] and 363 
degradation of neutrophil extracellular traps [52]. These actions all assist the bacteria in 364 
evading the immune system.  The reduction of DNase activity seen in over half the S. 365 
pseudintermedius tested (13/18) again suggests a role for manuka honey in reducing bacterial 366 
virulence and supporting host function in infection. It is possible that the significant decrease 367 
in DNase activity after treatment with sub MIC honey in in this study could be related to the 368 
significant reduction in aggregation seen here. The ability to agglutinate has been linked to 369 
the ability of isolates to form biofilms, an important mechanism of persistence [53].  370 
Aggregation is known to be partially depended on components displayed on the cell surface 371 
[54] but the role of DNase in staphylococcus sp. aggregation is less well understood. Some 372 
studies observe increased expression of DNase from planktonic cells [55] and others 373 
 o
n
 Septem
ber 10, 2020 by guest
http://aem
.asm
.org/
D
ow
nloaded from
 
Page 16 of 35 
 
describing increased expression of DNase from sessile cells [56]. It has been shown that the 374 
presence of extracellular DNA (eDNA) improves the ability of bacteria to aggregate and 375 
adhere to surfaces [57], therefore a reduction in DNase expression would be expected to lead 376 
to increased aggregation. As exposure to sub lethal concentrations of manuka honey led to a 377 
reduction in both DNase activity and bacterial aggregation, there could well be additional 378 
factors at work here. Further work to elucidate the mechanisms which cause these effects 379 
need to be undertaken.   380 
The ability to form and persist within, biofilms is a known Staphylococcus sp. virulence trait 381 
which decreases the susceptibility of in vivo populations to antimicrobial treatment and 382 
provides a reservoir for system infection [58]. Significant effort has been dedicated to 383 
removing and inactivating the biofilms of S. aureus and S. epidermidis, with manuka honey 384 
showing significant promise in both species [11, 59, 60]. The data presented here suggests 385 
that S. pseudintermedius isolates are likely no exception from this trend, with all the isolates 386 
within our collection showing a statistically significant reduction in mature biofilm biomass 387 
at manuka honey concentrations of ≥ 30 % (w/v). This suggests that manuka honey is able to 388 
disperse preformed biofilms, and individual bacterium which are shed form the biofilms will 389 
rapidly succumb to the antimicrobial effects which manuka honey clearly showed against 390 
planktonic populations.  391 
The data presented shows that in vitro manuka honey is able to reduce the activity of the 392 
virulence factors tested, however caution should be used when interpreting the data as the 393 
changes seen in vitro might not be replicated when tested  in vivo. Although the activity 394 
assays used within this study allow investigators to measure differences in activity of the 395 
supernatant this technique has limitations as it does not distinguish between an alteration in 396 
activity due to changes in protein efficiency or affects produced by changes in gene 397 
expression and/or protein production. In order to provide more information about the exact 398 
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mechanism of virulence factor modulation by manuka honey the technique used here must be 399 
combined with an analysis of gene presence (WGS), gene expression (qPCR and RNAseq) 400 
and protein expression (2D gel electrophoresis and mass spectrometry). This additional 401 
analysis is outside the scope of the current work, however, would be of significant interest to 402 
help elucidate the honeys mechanism of activity against S. pseudintermedius.  Further in vivo 403 
testing will be required to ensure that significant reductions in activity highlighted here 404 
translate to a biological difference in the virulence of the bacteria within animals and their 405 
owners. 406 
It is clear from the results presented here that manuka honey alone can effectively inhibit 407 
antibiotic sensitive and resistant S. pseudintermedius at low concentrations, and when 408 
combined with selected antibiotics can increase their efficacy. It is also apparent that the 409 
addition of sub lethal manuka honey to S. pseudintermedius has multiple effects on the 410 
virulence activity of those isolates with over half seeing a significant reduction in virulence 411 
activity in vitro. S. pseudintermedius is recognised as a major cause of post-operative 412 
infections in small animals, and more recently as a coloniser and opportunistic pathogen of 413 
humans [6]. Our data indicates that use of manuka honey in clinical treatment against S. 414 
pseudintermedius infections could be possible and that manuka honey could potentially be 415 
used as an antibiotic adjuvant for difficult to treat multi-antibiotic resistant strains. Further 416 
investigation via microbroth dilution on the effect of manuka honey on antibiotic sensitivity 417 
would help determine which interactions are antagonistic, indifferent or synergistic. In 418 
addition to this there is strong evidence that manuka honey could function as a topical 419 
antivirulence treatment to help reduce the severity of S. pseudintermedius infections and limit 420 
further colonisation.  Investigations into the mechanisms by which manuka honey is eliciting 421 
these effects needs to be undertaken to determine the mechanistic processes and strain 422 
specific effects seen.  423 
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 424 
Methods 425 
Strains and Culture conditions 426 
Eighteen S. pseudintermedius isolated from dogs were used throughout this study. All were 427 
provided by Nottingham Veterinary School, UK (18 isolates). These cultures were stored at -428 
80°C on cryobeads and revived on to Muller Hinton Agar (MHA) (Oxoid, UK) at 37 ᵒC 429 
before testing. Throughout the experiment Mueller Hinton Broth (MHB) was used where 430 
liquid medium was required. 431 
Antimicrobial agents  432 
Sterile medical grade manuka honey (Derma Sciences, Medihoney) was used throughout and 433 
was a gift from Derma Sciences, Europe. Antimicrobial susceptibility testing discs of; 434 
penicillin (1 unit), tetracycline (30 µg), chloramphenicol (30 µg), gentamicin (10 µg) and 435 
oxacillin (1 µg) were purchased from Oxoid (Hampshire, UK). These concentrations were 436 
chosen to match those with break points in the EUCAST breakpoint tables.  437 
DNA extraction/sequencing 438 
DNA was extracted from cultures using the Qiagen DNAeasy kit according to the 439 
manufacturer’s guidelines prior to quantifying yield and quality using spectrophotometric and 440 
fluorometric methods. DNA libraries for sequencing were constructed using the Illumina 441 
Nextera XT kit and sequenced on an Illumina MiSeq platform using a V3 reagent kit and 442 
2x300 bp reads. 443 
Genome Assembly and Analysis 444 
Raw sequence reads were passed through cutadapt (v2.0) [61] for the removal of nextera 445 
sequence adapters only prior to genome assembly using SPAdes (v3.12.0) in careful mode 446 
with read error correction and auto k-mer detection. [62]. Quast (v5.0.0) [63] was used to 447 
assess the quality of the genome assemblies. MLST allele sequences, IDs and isolate ST were 448 
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queried against the genome assemblies using the MLST tool (v2.16) (currently unpublished, 449 
Seemann T, mlst Github https://github.com/tseemann/mlst). A core SNP phylogeny was 450 
reconstructed using the isolates from this study along with 137 S. pseudintermedius genome 451 
assemblies obtained from NCBI and using variant sites called by SNIPPY (v4.3.2) (currently 452 
unpublished, Seemann T, SNIPPY Github https://github.com/tseemann/SNIPPY). 453 
Recombination was accounted for with the use of Gubbins (v 2.3.1) [64] prior to inference of 454 
a maximum-likelihood phylogenetic tree using FastTree (v 2.1.10), applying the generalized 455 
time-reversible model (gtr) [65]. A final tree was annotated with the use of iTOL[66]. The 456 
presence of antimicrobial resistance genes was determined using ABRICATE (v0.8.11) 457 
(Seemann T, Abricate, Github https://github.com/tseemann/abricate). A threshold of  > 90% 458 
sequence identity was used to determine a good match between the database genes and hits 459 
within the genome sequences. 460 
Minimum Inhibitory/Bactericidal Concentration Testing 461 
Minimum Inhibitory Concentration (MIC) of manuka honey antimicrobial susceptibility 462 
testing was completed using an adapted European Committee on Antimicrobial Susceptibility 463 
Testing methodology.  Briefly, mid-logarithmic growth phase cells were diluted to 0.5 464 
McFarland standard diluted 1 in 100 before it was mixed 1:1 with MHB to a final volume of 465 
200 µl (creating a cell density of ~5x105 CFU/ml) with the manuka honey set out as 2% w/v 466 
increments, diluted in MHB. The isolates were then grown for a period of 16-20 hours at 467 
37°C before measurement of optical density at a wavelength of 600nm (OD600). The MIC 468 
was considered to be the lowest concentration which inhibited cell growth (defined as blank 469 
corrected OD600 measurements equalling ≤0). The minimum bactericidal concentration 470 
(MBC) was determined by plating 10 µl of cells onto MHA from all wells showing no 471 
growth at 18 hrs and incubating for a further 18 hours at 37°C. The MBC was defined as the 472 
lowest concentration that reduced the viability of the initial bacterial inoculum ≥ 99.9%.  473 
 o
n
 Septem
ber 10, 2020 by guest
http://aem
.asm
.org/
D
ow
nloaded from
 
Page 20 of 35 
 
Positive control wells contained growth media and bacterial cells with no antibiotic or honey, 474 
negative control (used for blank correction) contained growth media and no cells. 475 
Antibiotic Disc Susceptibility  476 
Susceptibility of isolates to antibiotics alone and in combination with sub lethal 477 
concentrations of manuka honey was determined using disc diffusion on MHA.  Briefly the 478 
cells were diluted to 0.5 McFarland standard then using a sterile cotton swab a lawn plate was 479 
created and antibiotic discs were immediately applied using sterile forceps. The plates were 480 
incubated for 16-20 hours at 37 °C before the diameter of the zones of inhibition was 481 
measured. Zone sizes were interpreted using EUCAST Clinical Breakpoint Tables v. 9.0, 482 
where S. pseudintermedius breakpoints were unavailable those for S. aureus were used.  To 483 
screen for potential synergy between antibiotics and honey the disc diffusion assay was 484 
repeated with MHA supplemented post-sterilisation with a sub lethal dose of 5% (w/v) 485 
manuka honey.  486 
Virulence testing 487 
All isolates were screened for their ability to produce the virulence factors; haemolysin, 488 
protease, lipase, lecithinase and DNase. Agar plates were prepared by supplementing MHA 489 
with either: 5% (v/v) sheep blood, 5% (v/v) skim milk powder or 5% (v/v) egg yolk (Sigma, 490 
UK). Supplements were added after the media had been autoclaved and were mixed before 491 
pouring into plates. DNase agar was purchased directly from Sigma and prepared following 492 
manufactures guidelines. Prior to use the plates were equilibrated to room temperature and 5 493 
mm diameter wells were cut in the agar surface using a sterile cork borer. Overnight cultures 494 
were diluted to a density of OD600 0.8 – 1.0 (equivalent to a cell density of ~1 x 108 CFU/ml) 495 
and pelleted before resuspension in 0.4 % MHA, with or without 5% w/v honey. A volume of 496 
100 µl of this adjusted cell suspension was added to the plate wells and the plates cooled 497 
quickly to allow the soft agar to rapidly set and form a plug within the well. The plates were 498 
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then incubated for 24 hours at 37 ᵒC and a zone of activity around bacterial growth was 499 
recorded as a positive result for each virulence factor.  500 
Auto aggregation   501 
To assess aggregation overnight cultures were adjusted to OD600 0.9, 1 ml was transferred to 502 
1.5ml Eppendorf tube, centrifuged at 14,000 x g for 5 minutes and the pellet re-suspended in 503 
1 ml of phosphate buffered saline (Oxoid, UK; PBS) or PBS + honey (5 % (w/v). The 504 
inoculum was then transferred to microcuvettes and OD600 measured at 0 and 24 hours with 505 
static incubation at room temperature between the measurements. Bacterial cells that strongly 506 
agglutinate do not remain in the aqueous phase leading to a decrease in the OD600, if 507 
prevented from agglutinating the OD600 remains relatively stable. The percentage change of 508 
OD600 was calculated after 24 hours. Viable counts were taken using the Miles Misra method 509 
before and after incubation to confirm that any differences in auto aggregation were not due 510 
to cell death or proliferation.  511 
Biofilm assessment 512 
To determine the effect of manuka honey on mature biofilm S. pseudintermedius strains were 513 
diluted as described for MIC testing and diluted 1:1 with MHB to a final volume of 200 µl 514 
before incubating for 24 hours at 37°C to allow biofilm formation. Following incubation the 515 
supernatant was removed carefully from the wells, so as not to disturb the biofilm, and 516 
washed once with sterile PBS.  Manuka honey was diluted to concentrations of 10 to 50 % 517 
w/v increments in MHB. A volume of 200 µl of these solutions was added to the biofilms 518 
before incubating for a further 24 hours at 37°C. Following incubation, supernatant was 519 
removed and wells gently rinsed twice with PBS before fixing remaining biofilms with 520 
methanol for 15 minutes and staining with crystal violet (1% v/v diluted in distilled water) for 521 
15 minutes. Excess stain was rinsed until water ran clear and wells were dried before adding 522 
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7% acetic acid (diluted in distilled water) for 15 minutes to dissolve the bound crystal violet. 523 
Absorbance was measured at a wavelength of 590 nm. 524 
The ability of the S. pseudintermedius strains to attach to surfaces and form biofilm was 525 
performed following the method and classification proposed by Stepanovic et al [22]. 526 
Biofilm cultures were established, fixed and stained as described above and then classified as 527 
weakly, moderately, or strongly adherent, based upon the following formula: ODC < OD ≤ 2 528 
x ODC  = weak adherence, 2 x ODC  < OD ≤ 4 x ODC = moderate adherence and 4 x ODC < 529 
OD = strong adherence. ODC was defined as three standard deviations above the mean OD of 530 
the negative (medium only) control.  531 
Statistical analysis 532 
All tests were performed in triplicate and as data was nonparametric (determined using a 533 
Shapiro-Wilk test) was analysed using Mann Whitney (auto aggregation) and Kruskal Wallis 534 
method for all other experiments (GraphPad Prism 8). Unless otherwise stated all bars in 535 
figures show median values and error bars represent 95% confidence limit.  536 
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Sequencing reads and genome assemblies from this study are available from NCBI via the 548 
BioProject record PRJNA561036 549 
Accession numbers: Isolate A (SAMN12347716,SRR9998529), Isolate B 550 
(SAMN12347717,SRR9998521,SRR9998530), Isolate C 551 
(SAMN12347718,SRR9998528,SRR9998519), Isolate D (SAMN12347719,SRR9998518), 552 
Isolate E (SAMN12347720,SRR9998522), Isolate F (SAMN12347721,SRR9998525), Isolate 553 
G (SAMN12347722,SRR9998517), Isolate H (SAMN12347723,SRR9998524), Isolate I 554 
(SAMN12347724,SRR9998523), Isolate J (SAMN12347725,SRR9998520), Isolate K 555 
(SAMN12347726,SRR9998533), Isolate M (SAMN12347727,SRR9998534), Isolate N 556 
(SAMN12347728,SRR9998535), Isolate O (SAMN12347729,SRR9998536), Isolate P 557 
(SAMN12347730,SRR9998526,SRR9998527), Isolate Q (SAMN12347731,SRR9998531), 558 
Isolate T (SAMN12347732,SRR9998516), Isolate X (SAMN12347733,SRR9998532) 559 
 560 
Figure legends 561 
Supplementary Table 1: Antibiotic resistance genes and products present in S. 562 
pseudintermedius isolates identified using ABRICATE.  A threshold of >90% sequence 563 
identity was used to determine a good match between the database genes and hits within the 564 
genome sequences (see attached excel file). 565 
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Figures and Tables 808 
 809 
Table 1: A summary of the antibiotic resistance genes found by sequencing for each isolate  810 
 811 
 812 
 813 
 814 
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 815 
Figure 1: A maximum likelihood phylogeny of 156 Staphylococcus pseudintermedius isolates reconstructed 816 
from core SNPs, with removal of detected recombination sites. Samples sequenced in this study are 817 
distributed across the tree as noted by the outer black triangle. Coloured bars indicate geographical location 818 
of isolation source. Isolates with metadata related to host health have terminal nodes coloured green for 819 
healthy or red for confirmed infection. 820 
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 823 
Figure 2:  Graph A-E shows the zone diameter in mm of tetracycline, penicillin, chloramphenicol 824 
gentamicin and oxacillin respectively against 18 isolates of S. pseudintermedius in MHB (Control) and with 825 
a sub lethal concentration of manuka honey, 5% (w/v) (Treated). Those isolates showing a significant 826 
changes in sensitivity are marked with asterisk (** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001). Data points 827 
show median values and error bars represent 95% confidence limit. 828 
 829 
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 830 
Figure 3:  Manuka honey is able to inhibit virulence factor production by S. pseudintermedius. DNase (A), 831 
Haemolytic (B) proteolytic (C) and activity of the 18 S. pseudintermedius isolates in the absence (Control) 832 
or presence (Treated) of a sub lethal (5% w/v) concentration of manuka honey. Those isolates showing a 833 
significant changes in sensitivty are marked with asterisk (** p ≤ 0.01, **** p ≤ 0.0001). Data points show 834 
median values and error bars represent 95% confidence limit. 835 
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 836 
 837 
 838 
Figure 4:  The ability of S. pseudintermedius isolates to aggregate is reduced in the presence of sub 839 
inhibitory 5% (w/v) manuka honey. A shows the effect of sub lethal (5% w/v) manuka honey on 18 S. 840 
pseudintermedius isolates. Isolates showed a significant decrease (p = ≤0.001) in their ability to aggregate 841 
when treated with 5% w/v/ manuka honey. B shows the effect of increasing concentrations of manuka honey 842 
on preformed 24 h biofilms with a significant (**p = ≤ 0.01 and *** p = 0.001) reduction in biofilm seen at 843 
concentrations ≥ 30% w/v. Data points indicate median values and error bars represent the 95% confidence 844 
limit. 845 
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